How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?

2.50
Hdl Handle:
http://hdl.handle.net/10541/68741
Title:
How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?
Authors:
Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Chan, Clara
Abstract:
The outcome for patients with follicular lymphoma (FL) has substantially improved over the last few years. This improved survival appears to be largely related to the increasingly widespread use of anti-CD20 monoclonal antibody (mAb) rituximab in the therapy of FL today, either in combination with chemotherapy, for remission 'induction' and more recently as 'maintenance' therapy. Encouraging results have also been reported from radiolabelled anti-CD20 mAb or radioimmunotherapy (RIT), which exploits the unique method of action of this approach and high radiosensitivity of FL. High response rates and durable remissions have been seen with both (90)Y Ibritumomab tiuxetan and (131)I Tositumomab, and more recently compelling data are emerging demonstrating the efficacy of using these drugs as consolidation after initial treatment with chemotherapy or rituximab plus chemotherapy combinations. This review will focus on the current approaches and explore the data that has led to the emergence of a new nomenclature appearing in the language of clinicians involved in the treatment of FL, namely 'induction' therapy, 'consolidation' of initial response and 'maintenance' therapy. The current treatment approaches that have led to such increased optimism regarding the therapeutic outcome in FL are evaluated and discussed.
Affiliation:
School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uk
Citation:
How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? 2008, 49 (7):1263-73 Leuk. Lymphoma
Journal:
Leukemia & Lymphoma
Issue Date:
Jul-2008
URI:
http://hdl.handle.net/10541/68741
DOI:
10.1080/10428190802090805
PubMed ID:
18604715
Type:
Article
Language:
en
ISSN:
1029-2403
Appears in Collections:
All Paterson Institute for Cancer Research; Clinical Oncology; School of Cancer and Imaging Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorIllidge, Timothy M-
dc.contributor.authorChan, Clara-
dc.date.accessioned2009-05-21T16:42:21Z-
dc.date.available2009-05-21T16:42:21Z-
dc.date.issued2008-07-
dc.identifier.citationHow have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? 2008, 49 (7):1263-73 Leuk. Lymphomaen
dc.identifier.issn1029-2403-
dc.identifier.pmid18604715-
dc.identifier.doi10.1080/10428190802090805-
dc.identifier.urihttp://hdl.handle.net/10541/68741-
dc.description.abstractThe outcome for patients with follicular lymphoma (FL) has substantially improved over the last few years. This improved survival appears to be largely related to the increasingly widespread use of anti-CD20 monoclonal antibody (mAb) rituximab in the therapy of FL today, either in combination with chemotherapy, for remission 'induction' and more recently as 'maintenance' therapy. Encouraging results have also been reported from radiolabelled anti-CD20 mAb or radioimmunotherapy (RIT), which exploits the unique method of action of this approach and high radiosensitivity of FL. High response rates and durable remissions have been seen with both (90)Y Ibritumomab tiuxetan and (131)I Tositumomab, and more recently compelling data are emerging demonstrating the efficacy of using these drugs as consolidation after initial treatment with chemotherapy or rituximab plus chemotherapy combinations. This review will focus on the current approaches and explore the data that has led to the emergence of a new nomenclature appearing in the language of clinicians involved in the treatment of FL, namely 'induction' therapy, 'consolidation' of initial response and 'maintenance' therapy. The current treatment approaches that have led to such increased optimism regarding the therapeutic outcome in FL are evaluated and discussed.en
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshTreatment Outcome-
dc.titleHow have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uken
dc.identifier.journalLeukemia & Lymphomaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.